MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) hit a new 52-week high on Friday . The stock traded as high as $9.34 and last traded at $9.29, with a volume of 653860 shares changing hands. The stock had previously closed at $9.23.
Analysts Set New Price Targets
Several analysts have recently commented on the company. Craig Hallum reduced their target price on MiMedx Group from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Cantor Fitzgerald reissued an "overweight" rating and issued a $11.00 price objective on shares of MiMedx Group in a research note on Thursday, August 1st. Finally, StockNews.com lowered MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 8th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $12.00.
Read Our Latest Research Report on MiMedx Group
MiMedx Group Price Performance
The stock has a market capitalization of $1.36 billion, a P/E ratio of 16.87 and a beta of 1.94. The business has a fifty day simple moving average of $6.30 and a 200 day simple moving average of $6.77. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10.
Hedge Funds Weigh In On MiMedx Group
A number of hedge funds have recently bought and sold shares of the company. Isthmus Partners LLC boosted its stake in shares of MiMedx Group by 30.4% in the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company's stock worth $27,000 after buying an additional 91,714 shares during the last quarter. Headlands Technologies LLC purchased a new position in MiMedx Group in the first quarter worth $27,000. Blue Trust Inc. bought a new position in MiMedx Group in the 3rd quarter valued at $30,000. Point72 Asset Management L.P. bought a new position in MiMedx Group in the 2nd quarter valued at $40,000. Finally, Point72 DIFC Ltd increased its position in shares of MiMedx Group by 127.6% during the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock valued at $45,000 after purchasing an additional 4,275 shares during the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.
About MiMedx Group
(
Get Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Recommended Stories
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
